Omnia diagnostics pdf#

We are committed to supporting the ongoing fight against COVID-19 as well as expanding the availability of tools with broader applicability.” James Klein, president of Qorvo Biotechnologies, said, “Widespread testing with rapid and reliable results plays a critical role in helping public health officials respond to infectious disease outbreaks. “Qorvo’s antigen test has a lot of potential with near-PCR-level accuracy for use at point-of-care settings.” “Qorvo’s RF-based diagnostic technology has met review criteria to become a part of the RADx portfolio,” said Tiffani Bailey Lash, Ph.D., Co-Program Lead for the RADxTech program.

NIH launched RADx in the early months of the pandemic to speed innovation in the development and commercialization of technologies for COVID-19 testing. BAW sensor technology enables low Limit of Detection (LOD) levels that are similar to molecular testing capability. The Qorvo Omnia platform represents a paradigm shift in diagnostic testing capability by using high frequency Bulk Acoustic Wave (BAW) sensors to achieve rapid SARS-CoV-2 (COVID-19) antigen testing. Qorvo Biotechnologies’ COVID-19 antigen test was recently granted emergency use authorization (EUA) by the U.S. The contract, awarded to Qorvo Biotechnologies, a wholly owned subsidiary of Qorvo, helps advance the production and market launch of the Qorvo Omnia™ diagnostic test platform. GREENSBORO, N.C., Ap(GLOBE NEWSWIRE) - Qorvo® (Nasdaq: QRVO), a leading provider of innovative radio frequency (RF) solutions that connect the world, has been awarded a $24.4 million contract with the National Institutes of Health (NIH) through the Rapid Acceleration of Diagnostics (RADx SM) initiative.

Omnia diagnostics pdf#

PDF Version Qorvo Omnia™ diagnostic test platform uses innovative radio frequency technology designed to achieve rapid and specific COVID-19 antigen results